| Test Name and Number |
Recommended Use |
Limitations |
Follow Up |
| Sedimentation Rate, Westergren (ESR) 0040325 Method: Westergren |
Differentiate IBD from IBS
|
|
|
| C-Reactive Protein 0050180 Method: Immunoturbidimetric |
Differentiate IBD from IBS
|
|
|
| Ova & Parasite Exam, Body Fluid 2002277 Method: Concentration Technique/Microscopic Evaluation |
Rule out infections |
|
|
| Clostridium difficile Toxins (A & B) by EIA 0065146 Method: Enzyme Immunoassay |
Rule out infections
|
|
|
| CBC with Platelet Count & Automated Differential 0040003 Method: Automated Cell Count with Flow Cell Differential |
Initial testing
|
|
|
| Saccharomyces cerevisiae Antibodies, IgG & IgA 0050564 Method: Enzyme-Linked Immunosorbent Assay |
Use S. cerevisiae antibodies, along with pANCA and OMP IgA for distinguishing Crohn disease (CD) from ulcerative colitis (UC) in patients with suspected inflammatory bowel disease Detection of both Saccharomyces IgG and IgA antibodies in the same serum specimen is highly specific for CD |
Results should be used in conjunction with clinical history, imaging and/or histological studies Test results may serve as adjunct diagnostic tools for CD |
|
| Inflammatory Bowel Disease Differentiation Extended Profile 2001608 Method: Enzyme-Linked Immunosorbent Assay/Indirect Fluorescent Antibody |
This panel includes Saccharomyces cerevisiae IgG, IgA, atypical pANCA and OMP IgA Use panel to distinguish CD from UC in patients with suspected inflammatory bowel disease |
Results should be used in conjunction with clinical history, imaging and/or histological studies Use of serology alone in predicting CD or UC is limited |
|
| Anti-Neutrophil Cytoplasmic Antibody, IgG 0050811 Method: Indirect Fluorescent Antibody |
Detection of atypical pANCA pattern in the absence of ASCA IgG and IgA antibodies is associated with UC |
Results should be used in conjunction with clinical history, imaging and/or histological studies Test results may serve as adjunct diagnostic tools in differentiating UC from CD |
|
| Crohn Disease Prognostic Panel 2001613 Method: Enzyme-Linked Immunosorbent Assay |
Components include saccharomyces cerevisiae antibody, IgG; laminaribioside carbohydrate antibody IgG; mannobioside carbohydrate antibody IgG; chitobioside carbohydrate antibody, IgA |
Test results alone are not diagnostic or prognostic Positive results may indicate an aggressive course of CD Absence of these antibodies does not rule out an aggressive course of CD |
|
| Calprotectin, Fecal 0092303 Method: Enzyme-Linked Immunosorbent Assay |
May be useful in monitoring severity of disease |
|
|